The chair the evaluation committee has prepared Final Draft Guidance (FDG) on olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer and submitted it to NICE.
This follows a rapid review of NICE technology appraisal guidance TA831. The review is based on an updated commercial arrangement. No new clinical evidence was considered. The committee consideration and discussion from TA831 still remain relevant and can be found on the NICE website.
The FDG has been sent to consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it and/or notify us of any factual errors. The FDG has been sent to commentators for information, who can consider notifying us of any factual errors only. Subject to any appeal by consultees, the FAD may be used as the basis for NICE's guidance on the use of the appraised technology in the NHS in England.
Please note that the appeal period for this appraisal will close at 5pm, Monday 24 April 2023.
-
-
-
Final appraisal document TA831 - Final Appraisal Document (PDF 353 KB)
-
Committee papers TA831 - Final Appraisal Document Committee papers (PDF 634 KB)
-
-
Committee papers TA831 - 2nd Appraisal Consultation Document Committee papers (PDF 688 KB)
-
-
Committee papers TA831 - 1st Appraisal Consultation Document Committee papers (PDF 5.77 MB)
This page was last updated: